Compare BRSP & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRSP | ANNX |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 738.7M | 812.7M |
| IPO Year | 2017 | 2020 |
| Metric | BRSP | ANNX |
|---|---|---|
| Price | $5.35 | $5.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $6.50 | ★ $16.50 |
| AVG Volume (30 Days) | 2.2M | ★ 4.4M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 11.03% | N/A |
| EPS Growth | ★ 75.24 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $330,587,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.54 | $16,320.74 |
| P/E Ratio | $177.67 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.87 | $2.03 |
| 52 Week High | $6.17 | $7.18 |
| Indicator | BRSP | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 43.09 | 47.94 |
| Support Level | $5.24 | $4.66 |
| Resistance Level | $5.46 | $5.65 |
| Average True Range (ATR) | 0.11 | 0.55 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 38.96 | 32.10 |
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.